\mathbf{r}			1				
μ	atic	nt	den	വവ	rar	۱hı	CC
	au	JIIL	uti	IIUE	Iab	,,,,	C3

Patient demographics
* Gender dmg_sex C Male (1)
Female (2)
* Ethnicity
C Hispanic or Latino (1)
Not Hispanic or Latino (2)
C Not reported (3)
* Race (select all that apply)
☐ American Indian or Alaskan Native dmg_native
□ Asian dmg_asian
□ Black or African American dmg_afamer
□ Native Hawaiian or other Pacific Islander dmg_island
□ White dmg_white
☐ Not reported dmg_norace
Demographics complete dmg_fcomplete □
Death date
Death Date: deathdt
Study participation
□ CLOVERS study_clovers
Enrollment date study_cloversenrolldt
Discontinuation date study_cloversdiscondt

Contact completion

☐ Contact information completed ci_fcomplete

Contact information has been completed.

Contact information has not been completed.

- Click "Save and return" to go back to the dashboard.
- Use the project menu to go to the "LTO Data" study.
- Enroll the subject in the "LTO Data" study if not already done.
- Click the "Edit subject" button and fill out the contact data form.
- Click "Save and return" to save changes.
- Use the project menu to return to the current study.

Randomization

	RAND complete randfcomplete □
	This form cannot be completed until after the screening form has been completed and the patient has been enrolled in the study.
	Date and time of randomization:
*	rand_dt * rand_tm
*	Location at time of randomization: rand_loc C ED (1) Ward (2) C ICU (3) OR (4) Other (5) * Specify: rand_locspec
*	Randomization assignment: rand_trt
	C Liberal Fluid Group (1)
	C Restrictive Fluid Group (2)
*	What was the randomization id provided by the randomization system?
	rand_randid

Ventilator History

VENTHX complete venthx_fcomplete □
Was the patient on mechanical ventilation (assisted breathing) between randomization and study day venthx_ventyn 28? Yes (1) No (0)
* First date of mechanical ventilation (assisted breathing): venthx_startdt
* Last date patient was on mechanical ventilation (assisted breathing): venthx_lastdt
Was patient already intubated (orotracheal, nasotracheal, tracheostomy tube) at the time of venthx_randint randomization? Yes (1) Was patient intubated (orotracheal, nasotracheal, tracheostomy tube) before study day 28? venthx_studyint Yes (1) No (0)
* Date of intubation: venthx_intdt Arrhythmia history
ARRHX complete arrhxfcomplete
Between randomization and study day 28, did the patient experience one or more episodes of 'supraventricular tachycardia' (SVT), new atrial fibrillation, new atrial flutter, or other atrial arrhythmia sustained for at least one minute? C Yes (1) C No (0)
* Did this occur in the first 24 hours after randomization? arrhx_atrialarr24 C Yes (1) C No (0)
Between randomization and study day 28, did the patient experience one or more episodes of ventricular tachycardia or ventricular fibrillation sustained for at least 15 seconds? C Yes (1) C No (0)
* Did this occur in the first 24 hours after randomization? arrhx_ventarr24 C Yes (1) C No (0)
ICU history
Was the patient admitted to an ICU between hospital admission and study day 28? icuhx_icuyn C Yes (1) No (0)

* Location prior to ICU admission: icuhx_icuyn

C ED (1)

Ward (2)

ICU (3)

OR (4)

Other (5)

* Specify: icuhx_iculocspec

Please record the initial ICU admission, all study hospital ICU discharges, and all re-admissions between randomization and study day 28.

	icul	hx_dischargeyn	_r1 ic	uhx_readmityn_r1
	Admission date	Discharged?	Discharge date	Re-admitted?
Initial	* icuhx_admitdt_r1	* C Yes (1) C No (0)	*icuhx_dischargedt_rl	* C Yes (1) C No (0)
Second	*_icuhx_admitdt_r2	* C Yes	*icuhx_dischargedt_r2	* C Yes
Third	* icuhx_admitdt_r3	* C Yes	*icuhx_dischargedt_r3	* C Yes
Fourth	* icuhx_admitdt_r4	* C Yes	*icuhx_dischargedt_r4	* C Yes
Fifth	* icuhx_admitdt_r5	* C Yes C No	*icuhx_dischargedt_r5	* C Yes

IC HX icuhx fcomplete

icuhx_dischargeyn_r5

icuhx_readmityn_r5

Vasopressor history

 $\begin{array}{ll} VASOHX \ complete & vasohx_fcomplete \\ \hline \\ \hline \end{array}$

* Was a vasopressor administered between 48 hours post-randomization and study day 28? vasohx_yn

C Yes (1)

O No (0)

* First date of vasopressor infusion (lasting more than 1 hour) between 48 hours postrandomization and study day 28:

vasohx_firstdt

* Last date of vasopressor infusion (lasting more than 1 hour) between 48 hours post-randomization and study day 28:

vasohx_lastdt

ARDS history

ARDSHX complete ardshx__fcomplete □

If the patient had ARDS at baseline, or developed ARDS between day 0 and day 7, an ARDS source document should be completed. * Did patient have ARDS at the time of randomization (based on the criteria in protocol section ardshx randyn 3.6.2)? C Yes (1) O No (0) * Did patient develop ARDS between randomization and study day 7? ardshx_randd7yn C Yes (1) C No (0) * Date of ARDS diagnosis: ardshx randd7dt * Worst severity of ARDS within first 7 days in study (based on P/F or imputed P/F): ardshx randd7sev C Mild (201-300) (1) ^C Moderate (100-200) (2) C Severe (< 100) (3) **RRT** history rrthx fcomplete RRTHX complete * Did patient receive new renal replacement therapy (RRT) (excluding dialysis for underlying chronic rrthx newyn renal failure) between randomization and day 28? O Yes (1) O No (0) * First date subject received RRT: rrthx firstdt * Last date subject received RRT: rrthx_lastdt **Medications history** MEDICHX complete medichx_fcomplete Were any of the following medications administered between randomization and study day 7? * Vitamin C: medichx vitc O Yes (1) C No (0) * Vitamin D: medichx_vitd O Yes (1) O No (0) * Thiamine: medichx thiamine C Yes (1) O No (0) * Corticosteroids: medichx_corticoster

^C Yes (1) ^C No (0)

Antibiotic use

ANTIBIOHX complete antibiohx fcomplete * Was any antimicrobial (antibiotic, antimycobacterial, antiviral) administered by any route (enteral, IV, antibiohx antimicrobyn IM) between presentation to the study hospital and study day 28? C Yes (1) O No (0) Date and time of first antiobiotic administration after hospital presentation: antibiohx antimicrobdt antibiohx_antimicrobtm Microbiology results MICROBIORES complete microbiores fcomplete * Were any positive blood cultures collected between study hospital presentation and 72 hours post microbiores pos randomization? ^C Yes (1) $^{\circ}$ No (0)Final review of presence of infection INFREV complete infrev fcomplete Final infection status should be arbitrated by an investigator. The source document should be signed by the investigator. * Arbitrated infection status: infrev status C Infection present (1) C Infection likely present (2) C Infection likely not present (3) Non-infectious diagnosis definitively identified (4) * Please specify definitive non-infectious diagnosis: infrev noninfecspec * With all of the data available at the conclusion of hospitalization, what was the likely primary source infrev primsrc of infection at the time of enrollment? C Pneumonia (1) C Urinary tract infection (2) C Intra-abdominal infection (3) C Skin or soft-tissue infection (4) Vascular catheter-related infection (5) C Central nervous system infection (6) C Endocarditis or endovascular infection (7) C Flu or other virus confirmed by testing (8) COVID-19 confirmed by testing (11) Other source of infection (9) C Unknown (10) * Please specify other source of infection: infrev primsrcspec

Study termination

	TERM complete termfcomplete □
k	Was the patient permanently withdrawn from the trial prior to study day 28? term_wd (Study completion does not qualify as withdrawing from the study.) C Yes (1)
	C No (0)
	* Date withdrawn: term wddt
	
	* Reason patient withdrew from CLOVERS: term wdspec
	
K	Was the patient discharged alive from the study hospital prior to day 90? term_disch C Yes (1)
	C No (0)
	* Date of first study hospital discharge:
	term_dischdt
	* Was the patient discharged directly to home from the study hospital? term_dischhomeyn C_{Yes} (1)
	C No (0)
	* Was the patient ultimately discharged to home prior to day 90? term_ultimatehome C Yes (1) C No (0)
	Complete day 90 status question below
	* Date of discharge to home:
	term_ultimatehomedt
k	Day 90 patient status: term_d90stat
	C Alive at day 90 (1)
	C Dead (2) C Alive but not yet day 90 (3)
	* Date of death:
	term deathdt
	
	* Status date:
	term_statusdt
	Patient is home, next follow up at day 90
	Patient is not home. Update status until day 90, death or "home", whichever comes first.
k	Was written consent obtained from the patient during the study hospitalization? term_consn
	C Yes (1)

C No (0)

```
* Why was the patient not consented? term_consn
C Patient died (1)
C Patient never regained decision-making capability (2)
C Patient declined further participation in the study (3)
C Other (9)

* Please specify:
term_consnspec
```

Study coenrollment

```
* Select all PETAL Network studies the patient was coenrolled into:

□ ROSE stco_rose
□ VIOLET stco_violet
□ not coenrolled in PETAL network studies stco_none
```

Inclusion / Exclusion

IE comp	olete iefcomplete
* Did patie	ent meet the following inclusion criteria? ie_incl
• A • H	age ≥ 18 years a suspected or confirmed infection Iypotension, defined as systolic blood pressure < 100 mmHg or mean arterial pressure < 65 mHg after a minimum of at least 1 liter fluid bolus (fluids inclusive of pre-hospital fluids)
O Yes	(1)
C No	(0)
	s who do not meet the inclusion criteria should not be entered into StudyTRAX. Please the CCC to remove the patient from the CLOVERS study.
* Reasons	for exclusion (select all that apply):
□ No	t Excluded ie_notexcl
□ Un	able to obtain informed consent ie_consent
□ Pre	egnancy ie_pregnancy
□ Pat	tient already received more than 3 liters of fluid (including pre-hospital volumes) ie_fluid
□ Ну	potension suspected to be due to non-sepsis cause (e.g. hemorrhagic shock) ie_nonsepticht
□ Blo	ood pressure is at known or reported baseline level ie_bpbaseline
□ Мо	ore than 4 hours elapsed since inclusion criteria met ie_toolong4
□ Мо	ore than 24 hours elapsed since <i>presentation</i> to the hospital ie_toolong24
□ Sev	vere volume depletion from an acute condition other than sepsis ie_voldep
□ Pul	Imonary edema or signs of overt fluid overload ie_pulmedem
□ De	cision to withhold or withdraw life-sustaining treatment (except in patients committed to full support except CPR) ie_withdraw
□ Im	mediate surgical intervention planned such that study procedures could not be followed ie_surgery
□ Pri	or enrollment in this study ie_alreadyenrolled
□ МІ	O refusal: ie_mdrefuse
c	protocol ie_mdrefusetype
	tending did not have time to consider whether both CLOVERS arms are consistent ie_mdtoobusy th good medical care options for this patient
□ Pat	ient or surrogate declined all study blood samples ie_noblood
□ Pat	ient or surrogate declined to provide consent ie_declined
☐ Sur	rrogate unavailable ie_nosurrogate
	ient no longer meets the hypotension inclusion criterion available SBP < 100 or MAP < 65 within 30 minutes of randomization, or not receiving a vasopressor infusion) ie_nohypotensive
□ No	t excluded but not enrolled ie_nene
* R	leason not enrolled: ie_nenespec
_	

Screening

SCR complete scrfcomplete □	
Date and time patient met all inclusion criteria:	
* scr critmetdt * scr critmettm	
Sci_critificturi	
* Month patient met inclusion criteria:	
C January (1)	
C February (2)	
C March (3)	
C April (4)	
C May (5)	
C June (6)	
C July (7)	
C August (8)	
C September (9)	
October (10)	
November (11)	
O December (12)	
* Patient age (randomized patients): scr_age	
years	
* Patient age (screen fails): scr_agescr	
years	
* Suspected primary source of infection at enrollment: scr_infsrc	
C Pneumonia (1)	
C Urinary tract infection (2)	
C Intra-abdominal infection (3)	
C Skin or soft-tissue infection (4)	
C Vascular catheter-related infection (5)	
C Central nervous system infection (6)	
C Endocarditis or endovascular infection (7)	
Flu/other virus confirmed by testing (8)	
COVID-19 confirmed by testing (11)	
Other source of infection (9)	
C Unknown (10)	
* Please specify: scr_infsrcspec	
* Were vasopressors infusing when the patient qualified? scr qualvasop	
O Yes (1)	
C No (0)	
* What was the systolic blood pressure (SBP) when the patient qualified? scr_qualsbp	
mmHg	
* What was the mean arterial pressure (MAP) when the patient qualified? scr_qualmap	
mmHg	
* The attending physician agrees that both CLOVERS arms are consistent with good medical care options for this patient.	r_cloversok
C Yes (1)	
C No (0)	
110 (0)	

- * Was the CLOVERS consent video used during the informed consent process for this patient? scr_video O Yes (1) O No (0) * Why was the video not used? C Video not available (1) C Patient not approached for consent (2) C Video not used for other reason (3) Eligibility status: scrstat_scrstatus
- C In screening (1) C Failed screening (2)
- C Passed screening (3)

Consent

Has informed consent been obtained for participation in the CLOVERS study? cons_consyn C Yes (1) No (0) * Was initial consent obtained from the patient or from a surrogate? cons_constype C Subject (1) Surrogate (2) Was consent obtained for the collection of samples for future genetic research in severe illness? cons_gensevere Yes (1) No (0) Was consent obtained for the collection of samples for future genetic research for other medical cons_genothers conditions? Yes (1) No (0) Was consent obtained for participation in the SHAMROC study? cons_shamroc Yes (1) No (0)
C Subject (1) C Surrogate (2) Was consent obtained for the collection of samples for future genetic research in severe illness? cons_gensevere C Yes (1) C No (0) Was consent obtained for the collection of samples for future genetic research for other medical cons_genothers conditions? C Yes (1) C No (0) Was consent obtained for participation in the SHAMROC study? cons_shamroc C Yes (1)
C Yes (1) C No (0) Was consent obtained for the collection of samples for future genetic research for other medical cons_genothers conditions? C Yes (1) C No (0) Was consent obtained for participation in the SHAMROC study? cons_shamroc C Yes (1)
conditions? C Yes (1) C No (0) Was consent obtained for participation in the SHAMROC study? cons_shamroc C Yes (1)
C Yes (1)
Medical history
MEDHX complete medhxfcomplete □
Is the patient on chronic dialysis? medhx_cdialysisyn Yes (1) No (0)
* Is there a serum creatinine value available in the previous year prior to hospital arrival that is a medhx_creatyn baseline (e.g. not acutely elevated)? C Yes (1)
No (0) * Most recent pre-hospital creatinine within the last year: medhx prehospcreat
mg/dL
* Lowest creatinine within the last year: medhx_creatl mg/dL
Is the patient on chronic home mechanical ventilation (does not include home non-invasive ventilation for sleep disordered breathing)? C Yes (1) No (0)
Height: medhx_height * C in C cm medhx_heightunits (1) medhx_heightunits
Weight: medhx_weight * C lbs C kg medhx_weightunits ———————————————————————————————————

medhx hosparrdt * medhx hosparrtm Date and time of hospital admission: medhx_hospadmdt * medhx_hospadmtm Patient discharged from ED without hospital admission medhx hospadmnone * Pre-hospital level of care: medhx_prehosp C Home independently (1) C Home with help from family/friends (2) C Home with professional help (3) C Intermediate care or rehab facility (e.g. goal is to get patient better) (4) C Nursing facility (e.g. goal is to meet patient's ongoing needs) (5) C Acute care hospital (6) C Homeless or living in a temporary shelter (7) C Adult family home or other non-medical institutional setting (8) Other (888) * Specify: medhx_prehospspec * COVID-19 status: medhx covid19 C Positive test within 3 weeks prior to admission (1) C Negative (only negative tests with 3 weeks prior to admission) (2) C Unknown (no test within 3 weeks prior to admission) (3) * Date of **first** positive COVID-19 test within the three weeks prior to admission: medhx covid19dt ☐ Date of COVID-19 test unknown medhx covid19dtunk

Charlson (and baseline co-morbidities)

CHARL complete

Charl fcomplete

* Is chronic health information available? charl yn

O Yes (1)

O No (0)

Indicate whether each condition was present at hospital admission and prior to randomization.

		Yes	No	
*	AIDS (do not include HIV-positive without AIDS criteria)	C	0	charl_aids
*	Leukemia (AML, CML, ALL, multiple myeloma)	0	0	charl_leuk
*	Malignant lymphoma	0	0	charl_lymph
*	Hemiplegia	0	О	charl_hemiplegia
*	Cerebrovascular disease	C	0	charl_cerebvasc
*	A prior myocardial infarction	0	О	charl_myoinfarc
*	Congestive heart failure	C	0	charl_congheart
*	Peripheral vascular disease	0	О	charl_perivasc
*	Dementia	0	0	charl_dementia

		Yes	No	
*	COPD	С	О	charl_copd
*	Connective tissue disease	C	0	charl_contis
*	Peptic ulcer disease	0	0	charl_ulcer
*	History of hypertension	0	О	charl_hypertension
*	HIV positive (without AIDS)	С	О	charl_hiv
*	Alcoholism (ever)	C	0	charl_alcoholism
*	Coronary artery disease	О	О	charl_cad
*	Rapidly fatal disease (patient likely to die from underlying illness within 30 days e.g. endstage AIDS, end-stage cancer, in hospice)	О	C	charl_fatal
*]	Solid tumor charl_tumor No solid tumor present (0) Solid tumor present (exclude if > 5 years from diagnosis) (1) Solid tumor with metastasis present (ever) (2) Liver disease charl_liver No liver disease present (0) Mild liver disease present (without portal hypertension, includes hepatitis)	chron	ic (1)
(Moderate/severe liver disease present (cirrhosis with portal HTN bleeding)	V or v	aricea	1 (2)
(Diabetes mellitus (DM) charl_diabetes No DM present (0) Uncomplicated DM present (no end organ damage present) (DM with end organ damage present (excludes diet controlled alor		(2)	
	Moderate to severe kidney disease charl_kidney No moderate to severe kidney disease present (0) Moderate to severe kidney disease present (Cr > 3, ESRD, charcked cKD stage 5 (eGFR < 15 mL/min/1.73m²) not on dialysis)	t diaş	gnosis	of (1)

Pre-randomization fluids

Enter the total volume infused for each of the solutions listed for the pre-randomization period (2 hours before study hospital presentation to randomization).

C Moderate to severe kidney disease present and patient is dialysis dependent (2)

mL	
	blfluid_ns
mL	blfluid_lr
mL	blfluid_bs
mL	blfluid_alb
	mL

		_
IV medications: (include only when volume administered is documented in the medical record; e.g. if no volume, do not estimate or calculate)	* mL	blfluid_iv
Blood products:	* mL	blfluid_blood
Other: (includes ¼ NS, ½ NS, sterile water, d5 alone, etc.)	* mL	blfluid_other
* Total fluid output prior to randomization:	blfluid_flout	
mL		
BLFLUID complete blfluidfcomp □	lete	
Baseline vasopressors		
BLVASO complete blvaso_fcomple	ete	
* Did the patient have a pre-existing form of (such as central venous catheter, port-a-cath, to Yes (1) No (0)		
* Did the patient have a new central venous a randomization? (such as central venous catheter, port-a-cath, 1 Yes (1) No (0)	-	blvaso_cvnew
* Were vasopressors administered between h C Yes (1) No (0)	ospital presentation and r	randomization? blvaso_prerand
* What was the route of pre-randomizatio C Peripheral line administration (1) C Central line administration (2) Both (3)	n vasopressor administra	ation? blvaso_prerandroute
* Was the patient on vasopressors (continuous C Yes (1) No (0)	s infusion) at the time of t	randomization? blvaso_yn
* Record infusion rate at time of randomiz	ation:	
☐ Dobutamine: * blvaso_dobutyn ——	μg/kg/min blva	so_dobut
Dopamine: * blvaso_dopayn	μg/kg/min blva	aso_dopa
☐ Epinephrine: * blvaso_epiyn ── Norepinephrine: *		aso_epi
blvaso_norepiyn — Neosynephrine: *		so_norepi so_neosyn
blvaso_neosynyn — □ Vasopressin: *		so_neosyn o_vasop
blvaso_vasopyn —	units/min blvas	u_vasup

Fluid type

Volume

Baseline vital s	signs
BLVITAL complete	blvit

BLVITAL complete blvital_fcomp	lete			
Please enter the most recent vital signs price	or to randomization.			
* Temperature: blvital_temp				
* C C C F blvital_	tempunits			
* Heart rate: blvital hr				
beats per min				
* Respiratory rate: blvital_rate				
breaths per min				
Blood pressure				
BP complete □ bp_fcomplete				
Please enter the most recent blood pressur	re prior to randomization.			
Please enter the blood pressure closest to	0800.			
* Systolic BP: bp_systolic				
* Diastolic BP: bp_diastolic				
	ne patient was on vasopressors? blvital_bpvasoyn			
c_{Yes} (1)				
^C No (0)				
Labs				
LABS complete ☐ lab	osfcomplete			
Enter the most recent values (if available) collected prior to randomization.				
For platelets and total bilirubin only: if platelets or total bilirubin are not available prior to randomization, enter the first available value up to 6 hours following randomization.				
Enter the values (if available) closest to 0800.				
* White blood cell count:	/mm³ labs_wbc			
* Hematocrit:	% labs_hematocrit			
Platelets: ×1000/mm³ labs_platelets				
* Sodium:	meq/L labs_sodium			
* Potassium:	meq/L labs_potassium			
* Chloride: meq/L labs_chloride				
Bicarbonate: meq/L labs_bicarbonate				

* BUN:	mg/dL labs_bun
* Creatinine:	mg/dL labs_creatinine
* Blood glucose:	mg/dL labs_bloodgluc
* Albumin:	g/dL labs_albumin
* Total bilirubin:	mg/dL labs_totalbili
* Lactate:	mmol/L labs_lactate
* PaO2:	mmHg labs_pao2
* FiO2 at time of PaO2:	(decimal) labs_pao2fio2
* SpO2:	% labs_spo2
* FiO2 at time of SpO2:	(decimal) labs_spo2fio2
Glasgow Coma Score	
GCS complete gcsfcomplete □	
Collect last available GCS prior to random	nization.
Collect the GCS score recorded closest to	0 0800.
* Is the patient on a sedative or neuromuscu C Yes (1) C No (0) C Not available (-99)	lar blocker? gcs_sedative
* Eye opening score: gcs_eye	
None (1) To pain (2) To voice (3) Spontaneous (4) Score not obtained (-99)	
* Motor response score: gcs_motor C Flaccid (1) Abnormal extension (2) Abnormal flexion (3) Flexion withdrawal (4) Localizes to pain (5) Obeys commands (6) Score not obtained (-99)	

```
* Verbal response score: gcs_verbal
  None, or generally unresponsive on ventilator (1)
  C Incomprehensible (2)
  C Inappropriate, or questionably oriented if on ventilator (3)
  Confused (4)
  Oriented, or appears oriented on ventilator (5)
  C Score not obtained (-99)
* Total GCS score: gcs total
Sample collection
 SAMP complete samp fcomplete
 * Was a sample collected at this time period? samp yn
  C Yes
 \circ No
  Actual date and time blood drawn for sample collection:
          samp dt
                               samp tm
  * Accession number: samp accno
  * Specify why sample was not collected: samp spec
Basic assessment of prior functioning
 PFUNC complete pfunc fcomplete
 Recent living status and hospitalization
* Patient location prior to current hospitalization: pfunc reside
  C Home independently (1)
  C Home with help (2)
  C Home with professional help (3)
  C Intermediate care or rehab facility (e.g., goal is to get patient better) (4)
  C Nursing facility (e.g., goal is to meet patient's ongoing needs) (5)
  C Acute care hospital (6)
  C Homeless or living in a temporary shelter (7)
  C Adult Family Home or other non-medical institutional setting (8)
  Other (888)
  C Not answered (777)
  * Specify other prior location:
```

ADLs and IADLs

pfunc residespec

Because of a health or memory problem, did the patient have any difficulty with the following? * Dressing, including putting on shoes and socks? pfunc dressing C Yes (1) \circ No (2)O Don't do (6)Can't do (7) O Don't know (8) (777)O Not answered * Walking across a room? pfunc walking C Yes (1) \circ No (2) O Don't do (6)Can't do **(7)** O Don't know (8) O Not answered (777)* Bathing or showering? pfunc bathing C Yes **(1)** \circ_{No} (2) C Don't do (6) Can't do (7) C Don't know (8) (777)O Not answered * Eating, such as cutting up their food? pfunc_eating C Yes (1) C No (2) O Don't do (6) Can't do (7) O Don't know (8) (777)Not answered * Getting in or out of bed? pfunc bed C Yes (1) C No (2) C Don't do (6)Can't do (7)C Don't know (8) C Not answered (777)

* Using the toilet, including getting up and down? pfunc_toilet

C Yes
C No (1)
C Don't do (6)
C Can't do (7)
C Don't know (8)

(777)

Not answered

*	Preparing a hot meal?	pfunc_cooking
	C Yes	(1)
	C No	(2)
	C Don't do	(6)
	C Can't do	(7)
	C Don't know	(8)
	C Not answered	(777)
*	Shopping for groceries?	nfine chonning
·	C Yes	prunc_snopping
	C No	(1)
	_	(2)
	C Don't do	(6)
	Cun i uo	(7)
	Don't know	(8) (777)
	C Not answered	(777)
*	Making phone calls?	pfunc_phoning
	∩ Yes	(1)
	C No	(1) (2)
	C Don't do	(6)
	Can't do	(7)
	C Don't know	(8)
	C Not answered	(777)
*	Taking medications?	pfunc_medicating
	O Yes	
	C No	$\begin{array}{c} (1) \\ (2) \end{array}$
	C Don't do	(2) (6)
	C Can't do	(7)
	C Don't know	(8)
	C Not answered	(777)
*	Managing their money, O Yes	such as paying their bills and keeping track of expenses? pfunc_money
	_	(1)
	C No	(2)
	- Don i uo -	(6)
	C Can't do	(7)
	C Don't know	(8)
	Not answered	(777)
*	Stooping, kneeling, or c	rouching? pfunc_stooping
	C Yes	(1)
	C No	(1) (2)
	C Don't do	(6)
	C Can't do	(7)
	C Don't know	(8)
	C Not answered	(777)
*	Lifting or carrying weigh	thts over 10 lbs, like a heavy bag of groceries? pfunc_lifting
	C Yes	1 _ 2
	C No	$\binom{1}{2}$
	C Don't do	(2)
	C Can't do	(6) (7)
	C Don't know	(7) (8)
	C Not answered	(777)
	ansmore	

- W	-	ers for the ADL/I	ADL survey above? p.	runc_respondent	
C					
	8 ()				
	or each of the follow everal years?	ving, has there be	en a change in the patient	's cognitive ability over the last	
	roblems with judgm inking)?	nent (e.g., problen	ns making decisions, bad	financial decisions, problems with	pfunc_ad8judge
С	Yes, a change	(1)			
С	No, no change	(0)			
С	Don't know	(2)			
С	Not answered	(-99)			
* L	ess interest in hobbi	ies or activities?	pfunc_ad8hobbies		
С	Yes, a change	(1)			
С	No, no change	(0)			
С	Don't know	(2)			
C	Not answered	(-99)			
* R	epeats the same thin	ngs over and ove	(questions, stories, or sta	atements)? pfunc_ad8repea	ts
С	Yes, a change	(1)			
С	No, no change	(0)			
C	Don't know	(2)			
С	Not answered	(-99)			
	rouble learning how ontrol)?	v to use a tool, ap	pliance, or gadget (e.g., V	CR, computer, microwave, remo	te pfunc_ad8learning
C	Yes, a change	(1)			
С	No, no change	(1) (0)			
C	Don't know	(2)			
C	Not answered	(-99)			
* F	orgets the correct m	nonth or year?	pfunc_ad8date		
С	Yes, a change	(1)			
С	No, no change	(0)			
С	Don't know	(2)			
C	Not answered	(-99)			
	rouble handling con lls)?	nplicated financia	l affairs (e.g., balancing cl	neckbook, income taxes, paying	pfunc_ad8finance
C	Yes, a change	(1)			
C	No, no change	(0)			
C	Don't know	(2)			
C	Not answered	(-99)			
* T	rouble remembering	g appointments?	pfunc_ad8appointr	nent	
C	Yes, a change	(1)			
С	No, no change	(0)			
С	Don't know	(2)			
C	Not answered	(-99)			

* Daily problems with thinking and/or memory? pfunc_ad8memory

C Yes, a change

(1) C No, no change (0)

O Don't know (2)

O Not answered (-99)

The AD8 should only be completed by a surrogate, not by the patient.

Fluid intake and output

OSFLUID complete
On day 1 collect totals starting from 24 hours post-randomization to the time of the intake and output 24-hour totals at your hospital. (see CRF instructions)
On days 2–7 collect totals at the most convenient time at your hospital. (see CRF instructions)
If the patient is not in the ICU, only include intake volume documented in the medical record (i.e., if not recorded, do not estimate or calculate).
* Total fluid intake on this study day?
mL osfluid_intake
* Is the patient in the ICU this study day? osfluid_icu C Yes (1) C No (0)
* Total fluid output on this study day: osfluid_totalout mL
* Total urine output on this study day: osfluid_urineout mL
* Were diuretics given on this study day? osfluid_diuretics C Yes (1) C No (0) Vasopressors
OSVASO complete
□ osvasofcomplete
* Did the patient receive vasopressors for more than 1 hour on this study day? OSVaSO_yn 'Yes No
* Record the highest dose of each vasopressor received on this study day:
osvaso_dobutyn * µg/kg/min osvaso_dobut
osvaso_dopayn Dopamine: * μg/kg/min osvaso_dopa*
osvaso_epiyn *
Epinephrine: µg/kg/min osvaso_epi osvaso_norepiyn
Norepinephrine: * µg/kg/min osvaso_norepi
OSVASO_neosynyn Neosynephrine: * μg/kg/min OSVASO neosyn
osvaso_vasopyn *
□ Vasopressin: units/min osvaso_vasop
Labs

CLOVERS Day 1-3

		OL
LABS complete		Da
labs_	_fcomplete	

Enter the most recent values (if available) collected prior to randomization.

For platelets and total bilirubin only: if platelets or total bilirubin are not available prior to randomization, enter the first available value up to 6 hours following randomization.

Enter the values (if available) closest to	0800.
* White blood cell count:	/mm³ labs_wbc
* Hematocrit:	% labs_hematocrit
* Platelets:	×1000/mm³ labs_platelets
* Sodium:	meq/L labs_sodium
* Potassium:	meq/L labs_potassium
* Chloride:	meq/L labs_chloride
* Bicarbonate:	meq/L labs_bicarbonate
* BUN:	mg/dL labs_bun
* Creatinine:	mg/dL labs_creatinine
* Blood glucose:	mg/dL labs_bloodgluc
* Albumin:	g/dL labs_albumin
* Total bilirubin:	mg/dL labs_totalbili
* Lactate:	mmol/L labs_lactate
* PaO2:	mmHg labs_pao2
* FiO2 at time of PaO2:	(decimal) labs_pao2fio2
* SpO2:	_ mmHg labs spo2
* FiO2 at time of SpO2:	(decimal) labs_spo2fio2
Glasgow Coma Score	
GCS complete	
□ gcs_fcomplete	
Collect last available GCS prior to rand	omization.
Collect the GCS score recorded closes	st to 0800.
* Is the patient on a sedative or neuromus C Yes (1) C No (0) C Not available (-99)	scular blocker? gcs_sedative

	CLOVERS
* Eye opening score: gcs_eye	Day 1-3
None (1)	
C To pain (2)	
C To voice (3)	
C Spontaneous (4)	
C Score not obtained (-99)	
* Motor response score: gcs_motor	
C Flaccid (1)	
C Abnormal extension (2)	
C Abnormal flexion (3)	
C Flexion withdrawal (4)	
C Localizes to pain (5)	
C Obeys commands (6)	
Score not obtained (-99)	
* Verbal response score: gcs_verbal	
None, or generally unresponsive on ventilator (1)	
C Incomprehensible (2)	
C Inappropriate, or questionably oriented if on ventilator (3)	
C Confused (4)	
Oriented, or appears oriented on ventilator (5)	
Score not obtained (-99)	
* Total GCS score:	
gcs_total	
<u>800_1</u> 0.m2	
Sample collection	
SAMP complete	
□ sampfcomplete	
* Was a sample collected at this time period? samp yn	
C Yes (1)	
$^{\circ}$ No (0)	
Actual date and time blood drawn for sample collection:	
* samp_dt	
* Accession number:	
samp accno	
* Specify why sample was not collected:	
samp spec	

OSFLUID complete

□ osfluid fcomplete

On **day 1** collect totals starting from 24 hours post-randomization to the time of the intake and output 24-hour totals at your hospital. (see CRF instructions)

On days 2–7 collect totals at the most convenient time at your hospital. (see CRF instructions)

If the patient is not in the ICU, only include intake volume documented in the medical record (i.e., if not recorded, do not estimate or calculate).

* Total fluid intake on this study day?

____ mL osfluid_intake

* Is the patient in the ICU this study day? osfluid icu

^C Yes (1)

 \circ No (0)

* Total fluid output on this study day: $osfluid_totalout$

ml

* Total urine output on this study day: osfluid_urineout

____ ml

* Were diuretics given on this study day? osfluid_diuretics

O Yes (1)

 $\circ_{No}(0)$

CLOVERS Study Intervention Period

For each time period, enter the total volume (mL) infused for each solution. Hour 0 is the time of randomization.

Fluid type Volume (Hours 0–6)		Volume (Hours 6–24)	
Normal saline (NS):	*ipfluid_ns6	* mL	ipfluid_ns24
Lactated Ringers (LR):	* ipfluid_lr6	* mL	ipfluid_lr24
Balanced Solutions / Plasmalyte:	* ipfluid_bs6	* mL	ipfluid_bs24
Albumin:	*ipfluid_alb6	* mL	ipfluid_alb24
IV medications: (include only when volume administered is	* mL	* mL	
documented in the medical record; e.g. if no volume, do not estimate or calculate)	ipfluid_iv6		ipfluid_iv24
Blood products:	*ipfluid_blood6	* mL	ipfluid_blood24
Other: (includes ¼ NS, ½ NS, sterile water, d5 alone, etc.)	* ipfluid_oth6	* mL	ipfluid_oth24
* What was the total volume of intravenous fluid as which the first vasopressor was initiated?	dministered between randon	nization and the time at	
mL	ipfluid_	_totvol	
Total urine output:	*ipfluid_uout6	* mL	ipfluid_uout24
Total fluid output:	*ipfluid_flout6	* mL	ipfluid_flout24
* Were diuretics given between randomization and			
C Yes (1) C No (0)	ipfluid_	diuretics	
			-

IPFLUID complete

□ ipfluid fcomplete

- * Was the full 2 liter infusion completed? ipfluid_full21
 - O Yes (1)
 - $^{\circ}$ No (0)
 - * Total amount of infusion given:

- * Why was the full infusion not completed? ipfluid infreas
 - C Volume overload (1)
 - C After 1st liter, HR<90 and SBP≥110 (or MAP≥70) and patient volume replete (2) and team decided not to give 2nd liter
 - Other (9)

* Please specify: ipfluid_infreasspec

CLOVERS Study Intervention Period

Intervention ventilator and oxygen use

For each time period, indicate whether the patient received the specified treatment.

Treatment	Before randomization	Hours 0–6	Hours 6–24	
High flow O2 (HFNC):	ipvent hfo2b	* C Yes	* C Yes	
	C No	C No pvent_hfo2	с _{No} h6	ipvent_hfo2h24
NIPPV / CPAP:	ipvent cpapb	* C Yes	* C Yes	invent enemb24
	c _{No} ij	ovent_cpap	h6 C No	ipvent_cpaph24
Invasive ventilation:	ipvent iventb	* C Yes	* C Yes	ipvent iventh24
	o _{No} ij	ovent_ivent	o _{No} h6	ipvent_iventii2+

IPVENT complete

□ ipvent__fcomplete


Intervention vasopressors

- * Were any vasopressors infused between randomization and 24 hours after randomization? ipvaso yn
 - C Yes (1)
 - O No (0)

Record any vasopressor used between randomization and 24 hours post randomization. (To enable a row, click on the checkbox in the left-most column.)

If a vasopressor was initiated **before** randomization, please include it and record the actual start time.

If a vasopressor is still infusing at 24 hours, leave the stop date/time blank and check the box in the "still infusing at 24 hours" column.



	Vasop	oressor ipvaso_name3	Star	t date	Start time	Sto	pp date	Stop time	Still infusing at 24 hours
ipvaso_adm3	0	Dopamine Epinephrine Norepinephrine		ipvaso_startdt3	*	*	ipvaso_stopdt3	*	still infusing ipvaso_infuse3
	О	Neosynephrine / phenylephrine			ipvaso_st	arttn	13	ipvaso_sto	optm3
	° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° °	Vasopressin ipvaso name4							
:		Dopamine							
ipvaso_adm4 □		Epinephrine Norepinephrine	*	ipvaso_startdt4	*	*	ipvaso_stopdt4	*	□ still infusing ipvaso_infuse4
		Neosynephrine / phenylephrine	-		ipvaso_st	– arttn	<u></u> 14	ipvaso_sto	- pptm4
	0	Vasopressin							
	* 0	ipvaso_name5							
	O	Dopamine							
ipvaso_adm5		Epinephrine					. 1.5		
	0	Norepinephrine	* -	ipvaso_startdt5	*	_	ipvaso_stopdt5	*	still infusing ipvaso_infuse5
	0	Neosynephrine / phenylephrine			ipvaso_st	arttn	15	ipvaso_sto	optm5
	0	Vasopressin							
	* 0	Dobutamine							
	0	Dopamine							
	O	Epinephrine	*		ų.	*		4	atill in Caina
		Norepinephrine	*		_ ^	·		still infusing	
		Neosynephrine / phenylephrine							
	С	Vasopressin							
	* 0	Dobutamine							
	0	Dopamine							
	0	Epinephrine	*		*	*		*	_ still infusing
		Norepinephrine	-		· · ·	_ "		· ———	still infusing
	0	Neosynephrine / phenylephrine							
	C	Vasopressin							
	* 0	Dobutamine							
	0	Dopamine							
	C	Epinephrine						ala.	will in Control
	0	Norepinephrine	* _		· ——	*		۰ 	still infusing
	0	Neosynephrine / phenylephrine							
	С	Vasopressin							

	Vaso	pressor	Start date	Start time	Stop date	Stop time	Still infusing at 24 hours
	* (Dobutamine					
	C	Dopamine					
	C	Epinephrine					
	C	Norepinephrine	*	*	*	*	still infusing
	C	Neosynephrine / phenylephrine					
	C	Vasopressin					
		ipvaso_name Dobutamine	10				
		Dopamine					
ipvaso_adm10) (Epinephrine	* * 1.10	4	*	. 4	still infusing ipvaso_infuse10
		Norepinephrine	* ipvaso_startdt10		* ipvaso_stopdt10		still infusing 1pvaso_infuse10
		Neosynephrine / phenylephrine	iţ	pvaso_start	ttm10	ipvaso_stop	otm10
	C	Vasopressin					
		Dobutamine					
		Dopamine					
_		Epinephrine	*	*	*	*	still infusing
		Norepinephrine					
		Neosynephrine / phenylephrine					
	C	Vasopressin					
	* 0	_ 00					
		Dopamine		*	*	*	still infusing
		Epinephrine	*				
		Norepinephrine	·				
	C	Neosynephrine / phenylephrine					
	C	Vasopressin					
		Dobutamine					
	C	Воршине		*	*	*	
_	C	Ерикринк	*				still infusing
	C	тогершершие	·				
		Neosynephrine / phenylephrine					
	C	Vasopressin					
		Dobutamine					
П	C	- °P					
		Epinephrine	*	*	*	*	still infusing
		Norepinephrine	·	·			still intusing
	C	Neosynephrine / phenylephrine					
	C	C Vasopressin					

Vasopressor Start date ipvaso_name15 * C Dobutamine C Dopamine	Start time	Stop date	Stop time	Still infusing at 24 hours
ipvaso_adm15 C Epinephrine				
□ ○ Norepinephrine * <u>ipvaso_startdt15</u>	*	* ipvaso_sto	pdt15 *	still infusing ipvaso_infuse15
Neosynephrine / iphenylephrine	vaso_start	ttm15	ipvaso_stop	otm15
C Vasopressin				
IPVASO complete □ ipvaso_	_fcomple	te		
			CLOVERS	
Intervention central line placement		Study I	ntervention	Period
IPCLP complete				
□ ipclpfcomplete				
* Was a venous central line inserted between randomization and 72 $^{\circ}$ Yes (1) $^{\circ}$ No (0)	hours after rand	domization? ipclp_	vclyn	
Date and time of first venous central line insertion between random randomization:	nization and 72	hours after		
*ipclp_insertiondt * ipclp_insertiontm				
For each of the following complications, indicate whether the compandomization and study day 28 as a result of any venous central randomization and 72 hours. * Catheter-related bloodstream infection? ipclp_blooding C Yes (1)	al line inserted			
^C No (0)				
* What was the highest grade of complication experienced? (1) \cap Grade $1-NA$	ipclp_bloo	odinfgrade		
(2) Grade 2 – Localized; local intervention indicated; oral in (e.g., antibiotic, antifungal, or antiviral)	ntervention indi	icated		
(3) Grade 3 – IV antibiotic, antifungal, or antiviral intervention indicated				
(4) C Grade 4 – Life-threatening consequences; urgent intervention	ention indicated	d		
(5) Grade 5 – Death (as a result of the catheter-related block	odstream infect	tion)		
* Catheter-related deep-vein thrombosis? ipclp_dvt C Yes (1)				
C No (0)				
* What was the highest grade of complication experienced?	ipclp_dvtg	grade		
(1) C Grade 1 – TPA administration into line with no intent fo indicated	or systemic thera	ару		
(2) Grade 2 – Device dislodgement, blockage, leak, or mal replacement indicated	lposition; devic	e		
(3) Crade 3 – Pulmonary embolism, deep vein or cardiac the indicated (e.g., anticoagulation, lysis, filter, invasive pro-	cedure)			
(4) Crade 4 – Life-threatening consequences with hemodyn instability	namic or neurol	logic		
(5) Grade 5 – Death (as a result of the deep-vein thrombos	sis)			

```
* Pneumothorax? ipclp pneumothorax
  ° Yes (1)
  O No (0)
  * What was the highest grade of complication experienced? ipclp pneumothoraxgrade
(1) Grade 1 – Asymptomatic; clinical or diagnostic observations only; intervention
        not indicated
(2) C Grade 2 – Symptomatic; intervention indicated
(3) C Grade 3 – Sclerosis and/or operative intervention indicated; hospitalization
(4) C Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) Grade 5 – Death (as a result of the pneumothorax)
* Arterial injury? ipclp artini
  ° Yes (1)
  O No (0)
  * What was the highest grade of complication experienced? ipclp artinigrade
 (1) ○ Grade 1 – NA
 (2) Grade 2 – Repair or revision not indicated
 (3) Grade 3 – Severe symptoms; limiting self care ADL (e.g., transient cerebral
        ischemia); repair or revision indicated
(4) C Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) Grade 5 – Death (as a result of the arterial injury)
* Venous injury? ipclp veninj
  O Yes (1)
  C No (0)
  * What was the highest grade of complication experienced? ipclp veninjgrade
(1) ○ Grade 1 – NA
(2) Grade 2 – Repair or revision not indicated
(3) Grade 3 – Symptomatic limiting self care ADL; repair or revision indicated
(4) C Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) Grade 5 – Death (as a result of the venous injury)
* Post-procedural hemorrhage (including hemothorax and insertion site bleeding)? ipclp pphemorr
  O Yes (1)
  O No (0)
  * What was the highest grade of complication experienced? ipclp pphemorrgrade
(1) C Grade 1 – Mild symptoms; intervention not indicated
(2) Grade 2 – Moderate bleeding requiring transfusion < 2 units of pRBCs
 (3) Grade 3 – Transfusion indicated of >= 2 units pRBCs; invasive intervention
 (4) C Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) Grade 5 – Death (as a result of the post-procedural hemorrhage)
* Post-procedural hematoma? ipclp pphemat
  ○ Yes (1)
  O No (0)
  * What was the highest grade of complication experienced? ipclp pphematgrade
(1) C Grade 1 – Mild symptoms; intervention not indicated
(2) Grade 2 – Minimally invasive evacuation or aspiration indicated
(3) Grade 3 – Transfusion; invasive intervention indicated
(4) Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) Grade 5 – Death (as a result of the post-procedural hematoma)
```

* Ventricular arrhythmia? ipclp_ventarrhyth
$^{\circ}$ Yes (1)
C No (0)
* What was the highest grade of complication experienced? ipclp_ventarrhythgrade
 (1) C Grade 1 – Asymptomatic, intervention not indicated (2) C Grade 2 – Non-urgent medical intervention indicated
(3) C Grade 3 – Urgent intervention indicated
(4) C Grade 4 – Life-threatening consequences; hemodynamic compromise
(5) C Grade 5 – Death (as a result of the ventricular arrhythmia)
* Atrial arrhythmia? ipclp atrarrhyth
C Yes (1)
C No (0)
* What was the highest grade of complication experienced? ipclp_atrarrhythgrade
(1) C Grade 1 – Asymptomatic, intervention not indicated
(2) Grade 2 – Non-urgent medical intervention indicated
(3) Grade 3 – Symptomatic, urgent intervention indicated; device (e.g., pacemaker); ablation; new onset
(4) C Grade 4 – Life-threatening consequences; requiring urgent intervention
(5) C Grade 5 – Death (as a result of the atrial arrhythmia)
* Infusion site extravasation? ipclp ise
$c_{Y \otimes (1)}$
$^{\rm C}$ No (0)
* What was the highest grade of complication experienced? ipclp_isegrade
$(1)_{C \text{ Grade } 1-NA}$
(2) C Grade 2 – Erythema with associated symptoms (eg, edema, pain, induration, phlebitis)
(3) C Grade 3 – Ulceration or necrosis, severe tissue damage; operative intervention indicated
(4) Grade 4 – Life-threatening consequences; urgent intervention indicated
(5) C Grade 5 – Death (as a result of the infusion site extravasation)
* Air embolism? ipclp_embolism
$_{\text{Yes}}$ (1)
$^{\circ}$ No (0)
Intervention peripheral venous catheter vasopressor infusion
IPPVC complete
□ ippvcfcomplete
* Were vasopressors infused through a peripheral venous catheter (ie, peripheral IV or midline) between randomization and 72 hours after randomization? ippvc_vasopressors
C Yes (1)
C No (0)
Date and time of first infusion of vasopressors through a peripheral venous catheter between randomization and 72 hours after randomization:
* ippvc_infdt * ippvc_inftm

* Did infusion site extravasation occur between randomization and study day 28 as a result of any infusion of vasopressors that occurred through a peripheral venous catheter between randomization and 72 hours?

 $ippvc_ise$

- $\circ_{Yes}(1)$
- O No (0)
- * What was the highest grade of complication experienced? $ippvc_isegrade$
- (1) C Grade 1 NA
- (2) $\stackrel{\text{C}}{=}$ Grade 2 Erythema with associated symptoms (eg, edema, pain, induration, phlebitis)
- (3) Grade 3 Ulceration or necrosis, severe tissue damage; operative intervention indicated
- (4) C Grade 4 Life-threatening consequences; urgent intervention indicated
- (5) Grade 5 Death (as a result of the infusion site extravasation)

Intervention date override

Was this instance of the "study intervention period" interval created incorrectly, and thus should be deleted?

intdtover_yn

- O Yes (1)
- O No (0)
- * Please enter the date that the CCC told you to enter here:

intdtover date

CLOVERS Protocol Deviation

PD complete	
□ pdfcomplete	
* Date deviation occurred:	
pd_devdt	
* Date deviation discovered:	
pd_devrepdt	
* Type of deviation: pd_devtype	
C Eligibility error (1) C Randomization error (3)	
C Sample error (4)	
C Consent error (5)	
C Other (888)	
* Please specify: pd_other	
* Describe deviation:	
pd_desc	
* Describe steps taken to resolve the deviation and prevent future occurrences: pd_resolution	
-	
* Were study procedures temporarily or permanently discontinued as a result of this d	eviation? nd proceton
C Yes (1)	pu_procstop
^C No (0)	
* Was an adverse event reported as a result of this deviation? pd_ae	
C Yes (1) C No (0)	
Protocol deviation ID:	
pd_id	
1	

CLOVERS Adverse Event

AE complete	
□ aefcomplete	
Date and time of adverse event: * ae dt	
* ae_tm	
* COSTART term: ae_userterm	[lookup tool]
MedDRA code: ae_meddracode	
* Description of adverse event: ae_desc	
* Was the adverse event serious? ae_serious $\sim_{\rm Yes} (1)$ $\sim_{\rm No} (0)$	
* Was the adverse event related to study procedures? ae_relproc Definitely related (1) Probably or possibly related (2) Probably not related (3) Definitely not related (4) Uncertain relationship (5)	
* Was the adverse event unexpected (not listed in the investigator brochure or p $^{\circ}$ Yes (1) $^{\circ}$ No (0)	orotocol)? ae_unexpected
* What was the status of the adverse event at the time of the initial AE report? C Recovered (1) AE present, no treatment (2) AE present, being treated (3) Residual effect / no treatment (4) Residual effect / being treated (5) Deceased as a result of the AE (6)	ae_status
* What was the final outcome of the adverse event? Recovered (1) AE present, no treatment (2) AE present, being treated (3) Residual effect / no treatment (4) Residual effect / being treated (5) Deceased as a result of the AE (6) Date of recovery ae recdt	

Adverse event ID: ae_id

CLOVERS Adverse Event